Shares of Mirna Therapeutics Inc (NASDAQ:MIRN) have been given a consensus rating of “Hold” by the six ratings firms that are currently covering the firm. Six analysts have rated the stock with a hold recommendation. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $1.83.
Separately, Cantor Fitzgerald reissued a “hold” rating and set a $2.00 price target on shares of Mirna Therapeutics in a research report on Thursday, April 13th.
A hedge fund recently raised its stake in Mirna Therapeutics stock. Vanguard Group Inc. increased its position in Mirna Therapeutics Inc (NASDAQ:MIRN) by 15.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 178,387 shares of the biotechnology company’s stock after buying an additional 23,520 shares during the period. Vanguard Group Inc. owned approximately 0.86% of Mirna Therapeutics worth $391,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 28.38% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Mirna Therapeutics Inc (MIRN) Receives Average Recommendation of “Hold” from Brokerages” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/05/19/mirna-therapeutics-inc-mirn-receives-average-recommendation-of-hold-from-brokerages.html.
About Mirna Therapeutics
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Ratings for Mirna Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.